pSivida was founded in 1987 and is headquartered in Watertown, US

pSivida has an office in Watertown

Watertown, US (HQ)

480 Pleasant St, Suite B300

pSivida's revenue was reported to be $590 k in Q3, 2017

USD

## Revenue (Q3, 2017) | 590 k |

## Net income (Q3, 2017) | (5.1 m) |

## EBIT (Q3, 2017) | (5.2 m) |

## Market capitalization (18-Aug-2017) | 36.8 m |

## Cash (31-Mar-2017) | 12.9 m |

pSivida's current market capitalization is $36.8 m.

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Revenue | 3.5 m | 26.6 m | 1.6 m |

## Revenue growth, % | 665% | (94%) | |

## R&D expense | 9.6 m | 12.1 m | 14.4 m |

## General and administrative expense | 7.5 m | 8.1 m | 9 m |

## Operating expense total | 17 m | 20.1 m | 23.4 m |

## EBIT | (13.5 m) | 6.4 m | (21.8 m) |

## EBIT margin, % | (388%) | 24% | (1344%) |

## Interest income | 72 k | ||

## Pre tax profit | (13.5 m) | 6.4 m | (21.7 m) |

## Income tax expense | 130 k | (96 k) | 155 k |

## Net Income | (13.4 m) | 6.3 m | (21.5 m) |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 25.3 m | 521 k | 328 k | 466 m | 526 k | 324 k | 277 k | 6 m | 590 k |

## R&D expense | 2.8 m | 2.8 m | 3.3 m | 3.5 b | 3.7 m | 3.1 m | 4.2 m | 3.2 m | 3.3 m |

## General and administrative expense | 1.7 m | 1.9 m | 2 m | 2 b | 2 m | 2.3 m | 3.3 m | 2.9 m | 2.4 m |

## Operating expense total | 4.5 m | 4.6 m | 5.4 m | 5.5 b | 5.8 m | 5.4 m | 7.5 m | 6.1 m | 5.8 m |

## EBIT | 20.8 m | (4.1 m) | (5.1 m) | (5 b) | (5.2 m) | (5.1 m) | (7.2 m) | (94 k) | (5.2 m) |

## EBIT margin, % | 82% | (790%) | (1540%) | (1070%) | (996%) | (1573%) | (2594%) | (2%) | (875%) |

## Interest income | 3 k | 3 k | 6 k | ||||||

## Pre tax profit | 20.8 m | (4.1 m) | (5 m) | (5 b) | (5.2 m) | (5.1 m) | (7.2 m) | (67 k) | (5.1 m) |

## Income tax expense | (226 k) | 38 k | 44 k | 41 m | 42 k | 34 k | |||

## Net Income | 20.6 m | (4.1 m) | (5 m) | (4.9 b) | (5.2 m) | (5 m) | (7.2 m) | (67 k) | (5.1 m) |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 15.3 m | 19.1 m | 15.3 m |

## Accounts Receivable | 11.9 m | ||

## Inventories | 547 k | 681 k | 483 k |

## Current Assets | 19.3 m | 29.8 m | 30 m |

## PP&E | 297 k | 338 k | 290 k |

## Total Assets | 22.7 m | 32.4 m | 31.6 m |

## Accounts Payable | 464 k | 744 k | 1.4 m |

## Current Liabilities | 2.1 m | 3.3 m | 5.1 m |

## Total Liabilities | 10.7 m | ||

## Additional Paid-in Capital | 290.9 m | 293.1 m | 312.2 m |

## Retained Earnings | (277 m) | (270.7 m) | (292.2 m) |

## Total Equity | 14.9 m | 23.4 m | 20.9 m |

## Financial Leverage | 1.5 x | 1.4 x | 1.5 x |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 11.4 m | 29.8 m | 23 m | 14.1 m | 11.2 m | 24.9 m | 14.3 m | 11.7 m | 12.9 m |

## Current Assets | 40.7 m | 37.3 m | 33.1 m | 25.2 m | 21.9 m | 34.3 m | 23.5 m | 18.5 m | 16.5 m |

## PP&E | 261 k | 265 k | 280 k | 318 k | 311 k | 311 k | 257 k | 231 k | 241 k |

## Total Assets | 43.7 m | 40.2 m | 35.7 m | 27.5 m | 24 m | 36.2 m | 24.9 m | 19.7 m | 17.5 m |

## Accounts Payable | 1.1 m | 384 k | 812 k | 893 k | 303 k | 571 k | 1 m | 1.1 m | 741 k |

## Current Liabilities | 2.3 m | 2.3 m | 2.2 m | 3 m | 3.9 m | 4 m | 4.8 m | 4.9 m | 4.9 m |

## Additional Paid-in Capital | 291.2 m | 291.8 m | 292.4 m | 293.5 m | 294.3 m | 311.5 m | 313 m | 313.3 m | 316.2 m |

## Retained Earnings | (256.4 m) | (260.5 m) | (265.5 m) | (275.6 m) | (280.8 m) | (285.8 m) | (299.4 m) | (299.4 m) | (304.6 m) |

## Total Equity | 35.8 m | 32.3 m | 27.8 m | 18.8 m | 14.4 m | 26.6 m | 14.4 m | 14.8 m | 12.5 m |

## Financial Leverage | 1.2 x | 1.2 x | 1.3 x | 1.5 x | 1.7 x | 1.4 x | 1.7 x | 1.3 x | 1.4 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | (13.4 m) | 6.3 m | (21.5 m) |

## Depreciation and Amortization | 139 k | 112 k | 152 k |

## Inventories | 1.1 m | (136 k) | 187 k |

## Accounts Payable | (213 k) | 292 k | 626 k |

## Cash From Operating Activities | 8.4 m | 3.8 m | (3.8 m) |

## Purchases of PP&E | (248 k) | (161 k) | (113 k) |

## Cash From Investing Activities | 66 k | (6.7 m) | (4.5 m) |

## Cash From Financing Activities | 19 m | 235 k | 17 m |

## Income Taxes Paid | 263 k | 4 k |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 20.6 m | (4.1 m) | (5 m) | (4.9 b) | (5.2 m) | (5 m) | (7.2 m) | (67 k) | (5.1 m) |

## Accounts Payable | 1.1 m | 384 k | 812 k | 893 k | 303 k | 571 k | 1 m | 1.1 m | 741 k |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 29.5 k |

## Financial Leverage | 1.4 x |

July 14, 2016

* Results from investigator-sponsored phase 2 study of
Medidur showed no recurrence of uveitis in 11 eyes treated with
Medidur in 2 years after implant
Source text for Eikon:
Further company coverage: